Jared Kaltwasser

Elevated LDH and higher international prognostic index were also predictors of poor outcomes on bispecific antibodies, investigators found.

New research reveals light sensitivity significantly impacts quality of life in myasthenia gravis patients, highlighting the need for targeted treatment strategies.

The tool could make it easier for clinicians to rule out melanoma without the need for excision.

The combination of antifibrotic therapy and pulmonary vasodilator therapy improved transplant-free survival but had no significant impact on exercise capacity in pulmonary fibrosis and pulmonary hypertension.

A significant number of patients taking Bruton tyrosine kinase inhibitors (BTKis) for chronic lymphocytic leukemia (CLL) develop atrial fibrillation (AF).

Two studies explored the quality-of-life impacts of lebrikizumab for atopic dermatitis, finding its benefits extend beyond physical symptom improvements.

Clinical trials for idiopathic pulmonary fibrosis could benefit from improved patient engagement to include diverse perspectives and inclusive practices.

Individuals with rheumatoid arthritis face a higher risk of hospitalization for heart failure and pulmonary edema, a new report found.

Patients with a high tumor burden score had poorer outcomes following microwave ablation, the investigators found.

Forced oscillation technique (FOT) can enhance early detection and management of progressive pulmonary fibrosis.

Machine learning identifies key biomarkers predicting hydroxyurea resistance in polycythemia vera, enhancing early treatment strategies and patient outcomes.

Many studies have examined how rheumatoid arthritis therapy affects the risk of metabolic comorbidities.

Downstaging and bridging strategies are changing how hepatocellular carcinoma (HCC) is treated.

Efforts to more precisely select appropriate therapy for individual patients with rheumatoid arthritis have not yet yielded a clear-cut strategy, a new review finds.

New research suggests classical biomarkers cannot discriminate between refractory and non-refractory rheumatoid arthritis.

Minimal residual disease (MRD)-guided triple therapy showed promising results for relapsed chronic lymphocytic leukemia (CLL), achieving high rates of undetectable disease and prolonged survival.

Cardiovascular risk factors increase the risk of arterial and venous thrombosis in patients with myeloproliferative neoplasms, a study found.

Previous work had suggested pausing Bruton tyrosine kinase (BTK) inhibitors before COVID-19 vaccination might boost immunity in patients with chronic lymphocytic leukemia (CLL).

Recurrence-free survival rates were similar, even when patients quit adjuvant immunotherapy early, according to a new report.

Progression-free survival improvement and drug costs make zanubrutinib a more cost-effective option in relapsed or refractory chronic lymphocytic leukemia (CLL), new research suggests.

The immunotherapy improved outcomes compared with standard chemotherapy in the global Phase 3 DeLLphi-304 trial.

Investigators highlighted Raman spectroscopy, a noninvasive diagnostic technology that could lead to faster, earlier detection of skin cancer.

Patients with chronic lymphocytic leukemia (CLL) who experience Richter transformation have a poor prognosis, but ibrutinib may help boost the efficacy of chimeric antigen receptor T-cell therapies.

In a small study, lactotransferrin (LTF) was identified as a potentially important biomarker in extensive-stage small cell lung cancer (SCLC).

A number of recent trials have explored potential strategies for using immunotherapy in chronic lymphocytic leukemia (CLL).

Several studies have been conducted, but questions remain about where such therapies will fit into multiple myeloma treatment strategies.

The study highlights the importance of including patient self-assessment—and not just clinician assessment—when planning treatment in multiple myeloma.

The European LeukemiaNet (ELN) scoring system showed similar results to the more complicated Integrated Flow Score (iFS) for diagnosing myelodysplastic syndrome (MDS), including in low-risk patients.

Resmetirom offers a targeted approach to metabolic dysfunction–associated steatohepatitis (MASH) for use alongside lifestyle modifications.

Inclusion of female and Hispanic/Latino patients has increased over time, but most trials of metabolic dysfunction-associated steatohepatitis (MASH) still take place in high-income countries and have majority-White patient populations.